<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01469065</url>
  </required_header>
  <id_info>
    <org_study_id>B2611005</org_study_id>
    <nct_id>NCT01469065</nct_id>
  </id_info>
  <brief_title>A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes</brief_title>
  <official_title>A 2-week, Phase 1, Placebo-Controlled, Parallel Group Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Oral Doses Of PF-04991532 Given As Monotherapy To Adult Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a 2-week oral dose study of PF 04991532, performed in patients with type 2
      diabetes. Safety, pharmacokinetics (how the drug is distributed in the body), and
      pharmacodynamics (how the drug works in the body) will be studied. Patients may be asked to
      wash off their diabetes medication for 4-6 prior to study drug administration, and they will
      remain in the clinical research unit for a total of 20 days for baseline tests, 2 weeks of
      dosing, and some follow up tests.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline (Day -1) in Mean Daily Glucose at Day 14</measure>
    <time_frame>Baseline: hours -46, -44, -42, -40, -38, -36, -33, -and -30 on Day -1 (Day 1 morning dose was hour 0); Day 14: 2, 4, 6, 8, 10, 12, 15, and 18 hours after Day 14 morning dose</time_frame>
    <description>Mean daily glucose (MDG) was calculated based on the mean of 8 glucose measurements at pre-specified time points throughout the day on Day -1 and Day 14.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to 24 Hours Postdose (AUC24) of PF-04991532</measure>
    <time_frame>0 (before morning dose), 0.5, 1, 2, 3, 4, 6, 10, 10.5, 11, 12, 13, 15, 18, and 24 hours after morning dose on Day 1 and Day 14</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) from time zero to 24 hours post morning dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to 10 Hours Postdose (AUC10) of PF-04991532</measure>
    <time_frame>0 (before morning dose), 0.5, 1, 2, 3, 4, 6, and 10 hours after morning dose on Day 1 and Day 14</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) from time zero to 10 hours post morning dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration of PF-04991532 After Morning Dose Administration (Cmax(AM))</measure>
    <time_frame>0 (before morning dose), 0.5, 1, 2, 3, 4, 6, and 10 hours after morning</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration of PF-04991532 After Evening Dose Administration (Cmax(PM))</measure>
    <time_frame>10 (before evening dose), 10.5, 11, 12, 13, 15, 18, and 24 hours after morning dose on Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Plasma Trough Concentration (Cmin) of PF-04991532</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04991532 After Morning Dose Administration (Tmax(AM))</measure>
    <time_frame>0 (predose), 0.5, 1, 2, 3, 4, 6, and 10 hours after morning dose on Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04991532 After Evening Dose Administration (Tmax(PM))</measure>
    <time_frame>10 (before evening dose), 10.5, 11, 12, 13, 15, 18, and 24 hours after morning dose on Day 1 and Day 14</time_frame>
    <description>Time was computed as post morning dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F) of PF-04991532</measure>
    <time_frame>Day 1 and Day 14: 0 (before morning dose), 0.5, 1, 2, 3, 4, 6, 10 (before evening dose), 10.5, 11, 12, 13, 15, 18 and 24 hours after morning dose</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Accumulation Ratio of Area Under the Curve From Time Zero to 10 Hours Postdose of PF-04991532 (Rac)</measure>
    <time_frame>0 (before morning dose), 0.5, 1, 2, 3, 4, 6, and 10 hours after morning dose on Day 1 and Day 14</time_frame>
    <description>Area under the curve from time zero to 10 hours postdose of PF-04991532 (AUC10) of Day 14 divided by AUC10 of Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Accumulation Ratio of Maximum Observed Plasma Concentration of PF-04991532 After Morning Dose Administration (Rac, Cmax(AM))</measure>
    <time_frame>0 (before morning dose), 0.5, 1, 2, 3, 4, 6, and 10 hours after morning dose on Day 1 and Day 14</time_frame>
    <description>Maximum observed plasma concentration of PF-04991532 after morning dose administration (Cmax(AM)) of Day 14 divided by Cmax(AM) of Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Area Under the Curve From Time Zero to 24 Hours Postdose (AUC24(dn)) of PF-04991532</measure>
    <time_frame>0 (before morning dose), 0.5, 1, 2, 3, 4, 6, 10, 10.5, 11, 12, 13, 15, 18, and 24 hours after morning dose on Day 1 and Day 14</time_frame>
    <description>Area under the curve from time zero to 24 Hours Postdose (AUC24) divided by total daily dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Maximum Plasma Concentration After Morning Dose Administration (Cmax(AM)(dn)) of PF-04991532</measure>
    <time_frame>0 (before morning dose), 0.5, 1, 2, 3, 4, 6, and 10 hours after morning dose on Day 1 and Day 14</time_frame>
    <description>Maximum Observed Plasma Concentration of PF-04991532 after Morning Dose Administration (Cmax(AM)) divided by dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline (Day -2) in Mean Daily Glucose at Day 13</measure>
    <time_frame>Baseline: hours -72, -70, -68, -66, -62, -60, -57, and -54 on Day -2 (Day 1 morning dose was hour 0); Day 13: 0 (before morning dose), 2, 4, 6, 10, 12, 15 and 18 hours after Day 13 morning dose</time_frame>
    <description>Mean daily glucose (MDG) was calculated based on the mean of 8 glucose measurements at pre-specified time points throughout the day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Area Under the Curve of Glucose From Time 2 to 6 Hours Post Morning Dose (Glucose AUC(2-6)) Following Mixed Meal Tolerance Test (MMTT) at Day 14</measure>
    <time_frame>Baseline: hours -46, -45.75, -45.5, -45, -44.5, -44, -43, -and -42 on Day -1 (Day 1 morning dose was hour 0); Day 14: 2, 2.25, 2.5, 3, 3.5, 4, 5, and 6 hours after Day 14 morning dose</time_frame>
    <description>Area under the curve of glucose from time 2 to 6 hours post morning dose (Glucose AUC(2-6)) was calculated based on 8 glucose measurements at prespecified time points using the linear trapezoidal method. Nominal times were used in the calculation. Liquid meal was administered 2 hours post morning dose of PF-04991532 for mixed meal tolerance test (MMTT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG)</measure>
    <time_frame>Baseline: hour -48 on Day -1, hour -24 on Day 0, and hour 0 (before morning dose) on Day 1; hour 0 (before morning dose of each day) on Days 1, 2, 3, 6, and 10; and 24 hours after Day 14 morning dose on Day 15</time_frame>
    <description>The average of the Day -1 (hour -48), Day 0 (hour -24) and Day 1 pre-dose (hour 0) measurements was the baseline for fasting plasma glucose (FPG) analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Area Under the Curve of Insulin From Time 2 to 6 Hours Post Morning Dose (Insulin AUC(2-6)) Following Mixed Meal Tolerance Test (MMTT) at Day 14</measure>
    <time_frame>Baseline: hours -46, -45.75, -45.5, -45, -44.5, -44, -43, -and -42 on Day -1 (Day 1 morning dose was hour 0); Day 14: 2, 2.25, 2.5, 3, 3.5, 4, 5, and 6 hours after Day 14 morning dose</time_frame>
    <description>Area Under the Curve of Insulin from Time 2 to 6 Hours Post Morning Dose (Insulin AUC(2-6)) was calculated based on 8 insulin measurements at prespecified time points using the linear trapezoidal method. Nominal times were used in the calculation. Liquid meal was administered 2 hours post morning dose of PF-04991532 for mixed meal tolerance test (MMTT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Area Under the Curve of C-peptide From Time 2 to 6 Hours Post Morning Dose (C-peptide AUC(2-6)) Following Mixed Meal Tolerance Test (MMTT) at Day 14</measure>
    <time_frame>Baseline: hours -46, -45.75, -45.5, -45, -44.5, -44, -43, -and -42 on Day -1 (Day 1 morning dose was hour 0); Day 14: 2, 2.25, 2.5, 3, 3.5, 4, 5, and 6 hours after Day 14 morning dose</time_frame>
    <description>Area Under the Curve of C-peptide from Time 2 to 6 Hours Post Morning Dose (C-peptide AUC(2-6)) was calculated based on 8 C-peptide measurements at prespecified timepoints using the linear trapezoidal method. Nominal times were used in the calculation. Liquid meal was administered 2 hours post morning dose of PF-04991532 for mixed meal tolerance test (MMTT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Lipid Parameters at Day 14 and 16</measure>
    <time_frame>Baseline: hour -48 on Day -1, hour -24 on Day 0, and hour 0 on Day 1 for TG and Hour 0 (before morning dose) on Day 1 for TC, HDL, and LDL; 48 hours after morning dose on Day 16 for TG and Hour 0 (before morning dose) on Day14 for TC, HDL, and LDL</time_frame>
    <description>Baseline for fasting triglycerides (TG) was defined as the average of the Day -1 (hour -48), Day 0 (hour -24), and Day 1 pre-dose (hour 0) measurements. Baseline for fasting total cholesterol (TC), cholesterol (high-density lipoprotein (HDL)), and cholesterol (low-density lipoprotein (LDL)) was defined as the Day 1 pre-dose (hour 0) measurement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>PF-04991532</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-04991532 experimental study medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PF-04991532 Matching Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04991532</intervention_name>
    <description>Oral administration of PF-04991532; 25 mg given twice a day (BID) for 14 days</description>
    <arm_group_label>PF-04991532</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04991532</intervention_name>
    <description>Oral administration of PF-04991532; 75 mg given twice a day (BID) for 14 days</description>
    <arm_group_label>PF-04991532</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04991532</intervention_name>
    <description>Oral administration of PF-04991532; 150 mg given twice a day (BID) for 14 days</description>
    <arm_group_label>PF-04991532</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-0499132</intervention_name>
    <description>Oral administration of PF-04991532; 300 mg given twice a day (BID) for 14 days</description>
    <arm_group_label>PF-04991532</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration of PF-04991532 Matching Placebo; given twice a day (BID) for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 2 diabetes mellitus who are taking either no medication for the
             treatment of diabetes (diet/exercise therapy only), or who are taking only a single
             oral anti-diabetic drug (OAD) that can be temporarily discontinued for approximately
             8-10 weeks. For those taking a single OAD, treatment should be stable, where this is
             defined as no change in the treatment, including dose, over the past 3 months prior to
             Screening. OAD medications that are acceptable to be discontinued include: a
             sulfonylurea (SU), a meglitinide, a biguanide (eg, metformin), a dipeptidyl peptidase
             4 inhibitor (DPP-4i), or an alpha glucosidase inhibitor.

          -  Body Mass Index (BMI) of 18.5 to 45.0 kg/m2; and a total body weight &gt;50 kg (110 lbs).

          -  HbA1c &gt;/=7% and &lt;/=10% if the patient is on diet/exercise therapy only and does not
             require any OAD discontinuation. HbA1c &gt;/=6.5% and &lt;/=9% if the patient requires to be
             washed off an OAD.

        Exclusion Criteria:

          -  Evidence or history of diabetic complications with significant end organ damage.

          -  History of stroke or transient ischemic attack.

          -  History of myocardial infarction.

          -  History of coronary artery bypass graft or stent implantation.

          -  Clinically significant peripheral vascular disease.

          -  Any history or clinical evidence of congestive heart failure, NYHA Classes II IV.

          -  Current history of angina/unstable angina.

          -  One or more episodes of hypoglycemia within the last 3 months, or two or more episodes
             of hypoglycemia within the last 6 months.

          -  A positive urine drug screen.

          -  Use of tobacco or nicotine-containing products in excess of the equivalent of 10
             cigarettes per day.

          -  Blood pressure &gt;/=160 mm Hg (systolic) or &gt;/=100 mm Hg (diastolic), following at least
             5 minutes of rest.

          -  Pregnant or nursing females; females of childbearing potential.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hachioji-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2611005&amp;StudyName=A%202-week%20Trial%20Of%20PF-04991532%20In%20Patients%20With%20Type%202%20Diabetes</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2011</study_first_submitted>
  <study_first_submitted_qc>November 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2011</study_first_posted>
  <results_first_submitted>June 12, 2013</results_first_submitted>
  <results_first_submitted_qc>June 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 29, 2013</results_first_posted>
  <last_update_submitted>September 26, 2013</last_update_submitted>
  <last_update_submitted_qc>September 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inpatient</keyword>
  <keyword>diabetes</keyword>
  <keyword>phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>PF-04991532 matching placebo orally twice daily for 2 weeks.</description>
        </group>
        <group group_id="P2">
          <title>PF-04991532 25 mg</title>
          <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
        </group>
        <group group_id="P3">
          <title>PF-04991532 75 mg</title>
          <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
        </group>
        <group group_id="P4">
          <title>PF-04991532 150 mg</title>
          <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
        </group>
        <group group_id="P5">
          <title>PF-04991532 300 mg</title>
          <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>PF-04991532 matching placebo orally twice daily for 2 weeks.</description>
        </group>
        <group group_id="B2">
          <title>PF-04991532 25 mg</title>
          <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
        </group>
        <group group_id="B3">
          <title>PF-04991532 75 mg</title>
          <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
        </group>
        <group group_id="B4">
          <title>PF-04991532 150 mg</title>
          <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
        </group>
        <group group_id="B5">
          <title>PF-04991532 300 mg</title>
          <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="16"/>
            <count group_id="B5" value="17"/>
            <count group_id="B6" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="8.2"/>
                    <measurement group_id="B2" value="56.4" spread="9.0"/>
                    <measurement group_id="B3" value="57.4" spread="10.7"/>
                    <measurement group_id="B4" value="57.0" spread="9.4"/>
                    <measurement group_id="B5" value="56.1" spread="8.0"/>
                    <measurement group_id="B6" value="57.2" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (Day -1) in Mean Daily Glucose at Day 14</title>
        <description>Mean daily glucose (MDG) was calculated based on the mean of 8 glucose measurements at pre-specified time points throughout the day on Day -1 and Day 14.</description>
        <time_frame>Baseline: hours -46, -44, -42, -40, -38, -36, -33, -and -30 on Day -1 (Day 1 morning dose was hour 0); Day 14: 2, 4, 6, 8, 10, 12, 15, and 18 hours after Day 14 morning dose</time_frame>
        <population>The pharmacodynamic analysis population was defined as all randomized participants who received at least 1 dose of study medication (PF-04991532 or placebo) and had at least 1 of the pharmacodynamic parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>PF-04991532 matching placebo orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04991532 25 mg</title>
            <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04991532 75 mg</title>
            <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04991532 150 mg</title>
            <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O5">
            <title>PF-04991532 300 mg</title>
            <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Day -1) in Mean Daily Glucose at Day 14</title>
          <description>Mean daily glucose (MDG) was calculated based on the mean of 8 glucose measurements at pre-specified time points throughout the day on Day -1 and Day 14.</description>
          <population>The pharmacodynamic analysis population was defined as all randomized participants who received at least 1 dose of study medication (PF-04991532 or placebo) and had at least 1 of the pharmacodynamic parameters of interest.</population>
          <units>milligram/deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228.67" spread="36.26"/>
                    <measurement group_id="O2" value="233.20" spread="41.01"/>
                    <measurement group_id="O3" value="219.13" spread="38.16"/>
                    <measurement group_id="O4" value="229.92" spread="52.93"/>
                    <measurement group_id="O5" value="218.20" spread="53.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Day 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.98" spread="40.48"/>
                    <measurement group_id="O2" value="-17.55" spread="25.40"/>
                    <measurement group_id="O3" value="-3.67" spread="33.79"/>
                    <measurement group_id="O4" value="-9.73" spread="21.52"/>
                    <measurement group_id="O5" value="-29.23" spread="32.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio and 90% confidence interval (CI) were based on adjusted geometric mean. Natural log-transformed change from baseline in MDG (Day 14) was analyzed using ANCOVA with country and treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test. Formal statistical inference was not performed thus p value was not reported.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%)</param_type>
            <param_value>84.87</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>78.16</ci_lower_limit>
            <ci_upper_limit>92.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio and 90% confidence interval (CI) were based on adjusted geometric mean. Natural log-transformed change from baseline in MDG (Day 14) was analyzed using ANCOVA with country and treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%)</param_type>
            <param_value>89.80</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82.69</ci_lower_limit>
            <ci_upper_limit>97.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio and 90% confidence interval (CI) were based on adjusted geometric mean. Natural log-transformed change from baseline in MDG (Day 14) was analyzed using ANCOVA with country and treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%)</param_type>
            <param_value>87.15</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>80.27</ci_lower_limit>
            <ci_upper_limit>94.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio and 90% confidence interval (CI) were based on adjusted geometric mean. Natural log-transformed change from baseline in MDG (Day 14) was analyzed using ANCOVA with country and treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%)</param_type>
            <param_value>78.28</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>72.06</ci_lower_limit>
            <ci_upper_limit>85.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to 24 Hours Postdose (AUC24) of PF-04991532</title>
        <description>Area under the plasma concentration versus time curve (AUC) from time zero to 24 hours post morning dose</description>
        <time_frame>0 (before morning dose), 0.5, 1, 2, 3, 4, 6, 10, 10.5, 11, 12, 13, 15, 18, and 24 hours after morning dose on Day 1 and Day 14</time_frame>
        <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest; &quot;n&quot; is the number of participants analyzed for each day.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04991532 25 mg</title>
            <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04991532 75 mg</title>
            <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04991532 150 mg</title>
            <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04991532 300 mg</title>
            <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to 24 Hours Postdose (AUC24) of PF-04991532</title>
          <description>Area under the plasma concentration versus time curve (AUC) from time zero to 24 hours post morning dose</description>
          <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest; &quot;n&quot; is the number of participants analyzed for each day.</population>
          <units>nanogram*hour/milliliter (ng*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=16, 16, 16, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="441.6" spread="172.3"/>
                    <measurement group_id="O2" value="1745" spread="757.1"/>
                    <measurement group_id="O3" value="3899" spread="1549"/>
                    <measurement group_id="O4" value="6943" spread="3053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=16, 16, 16, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="487.4" spread="227.1"/>
                    <measurement group_id="O2" value="1892" spread="930.1"/>
                    <measurement group_id="O3" value="3870" spread="1369"/>
                    <measurement group_id="O4" value="7531" spread="3084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to 10 Hours Postdose (AUC10) of PF-04991532</title>
        <description>Area under the plasma concentration versus time curve (AUC) from time zero to 10 hours post morning dose.</description>
        <time_frame>0 (before morning dose), 0.5, 1, 2, 3, 4, 6, and 10 hours after morning dose on Day 1 and Day 14</time_frame>
        <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest; &quot;n&quot; is the number of participants analyzed for each day.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04991532 25 mg</title>
            <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04991532 75 mg</title>
            <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04991532 150 mg</title>
            <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04991532 300 mg</title>
            <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to 10 Hours Postdose (AUC10) of PF-04991532</title>
          <description>Area under the plasma concentration versus time curve (AUC) from time zero to 10 hours post morning dose.</description>
          <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest; &quot;n&quot; is the number of participants analyzed for each day.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=16, 16, 16, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="372.1" spread="146.7"/>
                    <measurement group_id="O2" value="1447" spread="749.3"/>
                    <measurement group_id="O3" value="3329" spread="1153"/>
                    <measurement group_id="O4" value="5661" spread="2595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=16, 16, 16, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="384.7" spread="181.9"/>
                    <measurement group_id="O2" value="1508" spread="920.7"/>
                    <measurement group_id="O3" value="2882" spread="1128"/>
                    <measurement group_id="O4" value="5551" spread="2633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration of PF-04991532 After Morning Dose Administration (Cmax(AM))</title>
        <time_frame>0 (before morning dose), 0.5, 1, 2, 3, 4, 6, and 10 hours after morning</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PF-04991532 25 mg</title>
            <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04991532 75 mg</title>
            <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04991532 150 mg</title>
            <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04991532 300 mg</title>
            <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration of PF-04991532 After Morning Dose Administration (Cmax(AM))</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=17, 16, 16, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.7" spread="57.36"/>
                    <measurement group_id="O2" value="486.6" spread="363.7"/>
                    <measurement group_id="O3" value="1285" spread="585.8"/>
                    <measurement group_id="O4" value="1951" spread="1106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=16, 16, 16, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.2" spread="74.23"/>
                    <measurement group_id="O2" value="469.8" spread="495.3"/>
                    <measurement group_id="O3" value="902.4" spread="489.1"/>
                    <measurement group_id="O4" value="1639" spread="917.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration of PF-04991532 After Evening Dose Administration (Cmax(PM))</title>
        <time_frame>10 (before evening dose), 10.5, 11, 12, 13, 15, 18, and 24 hours after morning dose on Day 1 and Day 14</time_frame>
        <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest; &quot;n&quot; is the number of participants analyzed for each day.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04991532 25 mg</title>
            <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04991532 75 mg</title>
            <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04991532 150 mg</title>
            <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04991532 300 mg</title>
            <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration of PF-04991532 After Evening Dose Administration (Cmax(PM))</title>
          <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest; &quot;n&quot; is the number of participants analyzed for each day.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=16, 16, 16, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.10" spread="67.45"/>
                    <measurement group_id="O2" value="336.0" spread="219.7"/>
                    <measurement group_id="O3" value="932.0" spread="387.7"/>
                    <measurement group_id="O4" value="1645" spread="1132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=16, 16,16, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.99" spread="46.05"/>
                    <measurement group_id="O2" value="360.7" spread="288.8"/>
                    <measurement group_id="O3" value="772.4" spread="310.8"/>
                    <measurement group_id="O4" value="1687" spread="914.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Observed Plasma Trough Concentration (Cmin) of PF-04991532</title>
        <time_frame>Day 14</time_frame>
        <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04991532 25 mg</title>
            <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04991532 75 mg</title>
            <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04991532 150 mg</title>
            <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04991532 300 mg</title>
            <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Observed Plasma Trough Concentration (Cmin) of PF-04991532</title>
          <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1691" spread="1.373"/>
                    <measurement group_id="O2" value="5.249" spread="3.112"/>
                    <measurement group_id="O3" value="11.32" spread="8.126"/>
                    <measurement group_id="O4" value="21.15" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04991532 After Morning Dose Administration (Tmax(AM))</title>
        <time_frame>0 (predose), 0.5, 1, 2, 3, 4, 6, and 10 hours after morning dose on Day 1 and Day 14</time_frame>
        <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest; &quot;n&quot; is the number of participants analyzed for each day.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04991532 25 mg</title>
            <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04991532 75 mg</title>
            <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04991532 150 mg</title>
            <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04991532 300 mg</title>
            <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04991532 After Morning Dose Administration (Tmax(AM))</title>
          <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest; &quot;n&quot; is the number of participants analyzed for each day.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=17, 16, 16, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.500" upper_limit="1.95"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.500" upper_limit="6.00"/>
                    <measurement group_id="O3" value="1.83" lower_limit="1.00" upper_limit="1.95"/>
                    <measurement group_id="O4" value="1.00" lower_limit="0.500" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=16, 16, 16, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.500" upper_limit="1.95"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.500" upper_limit="6.00"/>
                    <measurement group_id="O3" value="1.83" lower_limit="0.500" upper_limit="6.00"/>
                    <measurement group_id="O4" value="1.45" lower_limit="1.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04991532 After Evening Dose Administration (Tmax(PM))</title>
        <description>Time was computed as post morning dose.</description>
        <time_frame>10 (before evening dose), 10.5, 11, 12, 13, 15, 18, and 24 hours after morning dose on Day 1 and Day 14</time_frame>
        <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest; &quot;n&quot; is the number of participants analyzed for each day.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04991532 25 mg</title>
            <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04991532 75 mg</title>
            <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04991532 150 mg</title>
            <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04991532 300 mg</title>
            <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04991532 After Evening Dose Administration (Tmax(PM))</title>
          <description>Time was computed as post morning dose.</description>
          <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest; &quot;n&quot; is the number of participants analyzed for each day.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=16, 16, 16, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" lower_limit="11" upper_limit="15"/>
                    <measurement group_id="O2" value="11.0" lower_limit="11" upper_limit="15"/>
                    <measurement group_id="O3" value="11.0" lower_limit="11" upper_limit="12"/>
                    <measurement group_id="O4" value="11.0" lower_limit="11" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=16, 16, 16, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" lower_limit="11" upper_limit="15"/>
                    <measurement group_id="O2" value="11.0" lower_limit="11" upper_limit="15"/>
                    <measurement group_id="O3" value="11.0" lower_limit="11" upper_limit="18"/>
                    <measurement group_id="O4" value="11.0" lower_limit="11" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Oral Clearance (CL/F) of PF-04991532</title>
        <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
        <time_frame>Day 1 and Day 14: 0 (before morning dose), 0.5, 1, 2, 3, 4, 6, 10 (before evening dose), 10.5, 11, 12, 13, 15, 18 and 24 hours after morning dose</time_frame>
        <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest; &quot;n&quot; is the number of participants analyzed for each day.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04991532 25 mg</title>
            <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04991532 75 mg</title>
            <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04991532 150 mg</title>
            <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04991532 300 mg</title>
            <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance (CL/F) of PF-04991532</title>
          <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
          <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest; &quot;n&quot; is the number of participants analyzed for each day.</population>
          <units>milliliter/minute (mL/min)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=16, 16, 16, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1886" spread="1112"/>
                    <measurement group_id="O2" value="1434" spread="844.7"/>
                    <measurement group_id="O3" value="1282" spread="431.5"/>
                    <measurement group_id="O4" value="1440" spread="607.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D14 (n=16, 16, 16, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1710" spread="1200"/>
                    <measurement group_id="O2" value="1322" spread="937.9"/>
                    <measurement group_id="O3" value="1292" spread="624.5"/>
                    <measurement group_id="O4" value="1327" spread="537.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Accumulation Ratio of Area Under the Curve From Time Zero to 10 Hours Postdose of PF-04991532 (Rac)</title>
        <description>Area under the curve from time zero to 10 hours postdose of PF-04991532 (AUC10) of Day 14 divided by AUC10 of Day 1</description>
        <time_frame>0 (before morning dose), 0.5, 1, 2, 3, 4, 6, and 10 hours after morning dose on Day 1 and Day 14</time_frame>
        <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04991532 25 mg</title>
            <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04991532 75 mg</title>
            <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04991532 150 mg</title>
            <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04991532 300 mg</title>
            <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Accumulation Ratio of Area Under the Curve From Time Zero to 10 Hours Postdose of PF-04991532 (Rac)</title>
          <description>Area under the curve from time zero to 10 hours postdose of PF-04991532 (AUC10) of Day 14 divided by AUC10 of Day 1</description>
          <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.095" spread="0.3520"/>
                    <measurement group_id="O2" value="1.049" spread="0.2995"/>
                    <measurement group_id="O3" value="0.9004" spread="0.3353"/>
                    <measurement group_id="O4" value="1.017" spread="0.2946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Accumulation Ratio of Maximum Observed Plasma Concentration of PF-04991532 After Morning Dose Administration (Rac, Cmax(AM))</title>
        <description>Maximum observed plasma concentration of PF-04991532 after morning dose administration (Cmax(AM)) of Day 14 divided by Cmax(AM) of Day 1</description>
        <time_frame>0 (before morning dose), 0.5, 1, 2, 3, 4, 6, and 10 hours after morning dose on Day 1 and Day 14</time_frame>
        <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04991532 25 mg</title>
            <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04991532 75 mg</title>
            <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04991532 150 mg</title>
            <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04991532 300 mg</title>
            <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Accumulation Ratio of Maximum Observed Plasma Concentration of PF-04991532 After Morning Dose Administration (Rac, Cmax(AM))</title>
          <description>Maximum observed plasma concentration of PF-04991532 after morning dose administration (Cmax(AM)) of Day 14 divided by Cmax(AM) of Day 1</description>
          <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.057" spread="0.6267"/>
                    <measurement group_id="O2" value="0.9655" spread="0.5913"/>
                    <measurement group_id="O3" value="0.7022" spread="0.4744"/>
                    <measurement group_id="O4" value="0.8663" spread="0.3648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Normalized Area Under the Curve From Time Zero to 24 Hours Postdose (AUC24(dn)) of PF-04991532</title>
        <description>Area under the curve from time zero to 24 Hours Postdose (AUC24) divided by total daily dose</description>
        <time_frame>0 (before morning dose), 0.5, 1, 2, 3, 4, 6, 10, 10.5, 11, 12, 13, 15, 18, and 24 hours after morning dose on Day 1 and Day 14</time_frame>
        <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest; &quot;n&quot; is the number of participants analyzed for each day.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04991532 25 mg</title>
            <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04991532 75 mg</title>
            <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04991532 150 mg</title>
            <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04991532 300 mg</title>
            <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Normalized Area Under the Curve From Time Zero to 24 Hours Postdose (AUC24(dn)) of PF-04991532</title>
          <description>Area under the curve from time zero to 24 Hours Postdose (AUC24) divided by total daily dose</description>
          <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest; &quot;n&quot; is the number of participants analyzed for each day.</population>
          <units>ng*hr/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=16, 16, 16, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.416" spread="1.723"/>
                    <measurement group_id="O2" value="5.810" spread="2.520"/>
                    <measurement group_id="O3" value="6.497" spread="2.578"/>
                    <measurement group_id="O4" value="5.787" spread="2.540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=16, 16, 16, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.874" spread="2.271"/>
                    <measurement group_id="O2" value="6.307" spread="3.107"/>
                    <measurement group_id="O3" value="6.449" spread="2.279"/>
                    <measurement group_id="O4" value="6.275" spread="2.558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Normalized Maximum Plasma Concentration After Morning Dose Administration (Cmax(AM)(dn)) of PF-04991532</title>
        <description>Maximum Observed Plasma Concentration of PF-04991532 after Morning Dose Administration (Cmax(AM)) divided by dose</description>
        <time_frame>0 (before morning dose), 0.5, 1, 2, 3, 4, 6, and 10 hours after morning dose on Day 1 and Day 14</time_frame>
        <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest; &quot;n&quot; is the number of participants analyzed for each day.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04991532 25 mg</title>
            <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04991532 75 mg</title>
            <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04991532 150 mg</title>
            <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04991532 300 mg</title>
            <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Normalized Maximum Plasma Concentration After Morning Dose Administration (Cmax(AM)(dn)) of PF-04991532</title>
          <description>Maximum Observed Plasma Concentration of PF-04991532 after Morning Dose Administration (Cmax(AM)) divided by dose</description>
          <population>The pharmacokinetic parameter analysis population was defined as all randomized participants treated with PF-04991532 who had at least 1 of the pharmacokinetic parameters of interest; &quot;n&quot; is the number of participants analyzed for each day.</population>
          <units>ng/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=17, 16, 16, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.754" spread="1.147"/>
                    <measurement group_id="O2" value="3.245" spread="2.431"/>
                    <measurement group_id="O3" value="4.283" spread="1.947"/>
                    <measurement group_id="O4" value="3.252" spread="1.842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=16, 16, 16, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.964" spread="1.484"/>
                    <measurement group_id="O2" value="3.132" spread="3.296"/>
                    <measurement group_id="O3" value="3.009" spread="1.631"/>
                    <measurement group_id="O4" value="2.732" spread="1.530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline (Day -2) in Mean Daily Glucose at Day 13</title>
        <description>Mean daily glucose (MDG) was calculated based on the mean of 8 glucose measurements at pre-specified time points throughout the day.</description>
        <time_frame>Baseline: hours -72, -70, -68, -66, -62, -60, -57, and -54 on Day -2 (Day 1 morning dose was hour 0); Day 13: 0 (before morning dose), 2, 4, 6, 10, 12, 15 and 18 hours after Day 13 morning dose</time_frame>
        <population>The pharmacodynamic analysis population was defined as all randomized participants who received at least 1 dose of study medication (PF-04991532 or placebo) and had at least 1 of the pharmacodynamic parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>PF-04991532 matching placebo orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04991532 25 mg</title>
            <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04991532 75 mg</title>
            <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04991532 150 mg</title>
            <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O5">
            <title>PF-04991532 300 mg</title>
            <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Day -2) in Mean Daily Glucose at Day 13</title>
          <description>Mean daily glucose (MDG) was calculated based on the mean of 8 glucose measurements at pre-specified time points throughout the day.</description>
          <population>The pharmacodynamic analysis population was defined as all randomized participants who received at least 1 dose of study medication (PF-04991532 or placebo) and had at least 1 of the pharmacodynamic parameters of interest.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day -2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214.31" spread="42.39"/>
                    <measurement group_id="O2" value="230.70" spread="37.88"/>
                    <measurement group_id="O3" value="207.98" spread="35.10"/>
                    <measurement group_id="O4" value="219.59" spread="43.78"/>
                    <measurement group_id="O5" value="204.68" spread="45.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Day 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.78" spread="39.66"/>
                    <measurement group_id="O2" value="-27.22" spread="25.34"/>
                    <measurement group_id="O3" value="-15.78" spread="31.99"/>
                    <measurement group_id="O4" value="-17.29" spread="17.75"/>
                    <measurement group_id="O5" value="-33.58" spread="37.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio and 90% confidence interval (CI) were based on adjusted geometric mean. Natural log-transformed change from baseline in MDG (Day 13) was analyzed using ANCOVA with country and treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%)</param_type>
            <param_value>82.69</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>76.06</ci_lower_limit>
            <ci_upper_limit>89.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio and 90% confidence interval (CI) were based on adjusted geometric mean. Natural log-transformed change from baseline in MDG (Day 13) was analyzed using ANCOVA with country and treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%)</param_type>
            <param_value>85.39</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>78.60</ci_lower_limit>
            <ci_upper_limit>92.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio and 90% confidence interval (CI) were based on adjusted geometric mean. Natural log-transformed change from baseline in MDG (Day 13) was analyzed using ANCOVA with country and treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%)</param_type>
            <param_value>85.37</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>78.59</ci_lower_limit>
            <ci_upper_limit>92.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio and 90% confidence interval (CI) were based on adjusted geometric mean. Natural log-transformed change from baseline in MDG (Day 13) was analyzed using ANCOVA with country and treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%)</param_type>
            <param_value>75.82</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>69.78</ci_lower_limit>
            <ci_upper_limit>82.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment difference and 90% confidence interval (CI) were based on adjusted geometric mean.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference between Test and Reference</param_type>
            <param_value>-35.84</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.89</ci_lower_limit>
            <ci_upper_limit>-18.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Area Under the Curve of Glucose From Time 2 to 6 Hours Post Morning Dose (Glucose AUC(2-6)) Following Mixed Meal Tolerance Test (MMTT) at Day 14</title>
        <description>Area under the curve of glucose from time 2 to 6 hours post morning dose (Glucose AUC(2-6)) was calculated based on 8 glucose measurements at prespecified time points using the linear trapezoidal method. Nominal times were used in the calculation. Liquid meal was administered 2 hours post morning dose of PF-04991532 for mixed meal tolerance test (MMTT).</description>
        <time_frame>Baseline: hours -46, -45.75, -45.5, -45, -44.5, -44, -43, -and -42 on Day -1 (Day 1 morning dose was hour 0); Day 14: 2, 2.25, 2.5, 3, 3.5, 4, 5, and 6 hours after Day 14 morning dose</time_frame>
        <population>The pharmacodynamic analysis population was defined as all randomized participants who received at least 1 dose of study medication (PF-04991532 or placebo) and had at least 1 of the pharmacodynamic parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>PF-04991532 matching placebo orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04991532 25 mg</title>
            <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04991532 75 mg</title>
            <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04991532 150 mg</title>
            <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O5">
            <title>PF-04991532 300 mg</title>
            <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Area Under the Curve of Glucose From Time 2 to 6 Hours Post Morning Dose (Glucose AUC(2-6)) Following Mixed Meal Tolerance Test (MMTT) at Day 14</title>
          <description>Area under the curve of glucose from time 2 to 6 hours post morning dose (Glucose AUC(2-6)) was calculated based on 8 glucose measurements at prespecified time points using the linear trapezoidal method. Nominal times were used in the calculation. Liquid meal was administered 2 hours post morning dose of PF-04991532 for mixed meal tolerance test (MMTT).</description>
          <population>The pharmacodynamic analysis population was defined as all randomized participants who received at least 1 dose of study medication (PF-04991532 or placebo) and had at least 1 of the pharmacodynamic parameters of interest.</population>
          <units>mg*hr/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1091.23" spread="163.30"/>
                    <measurement group_id="O2" value="1126.34" spread="119.26"/>
                    <measurement group_id="O3" value="1029.76" spread="154.84"/>
                    <measurement group_id="O4" value="1085.84" spread="245.64"/>
                    <measurement group_id="O5" value="1050.69" spread="241.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Day 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.05" spread="148.94"/>
                    <measurement group_id="O2" value="-84.44" spread="99.91"/>
                    <measurement group_id="O3" value="-12.65" spread="114.19"/>
                    <measurement group_id="O4" value="-60.55" spread="89.36"/>
                    <measurement group_id="O5" value="-158.93" spread="152.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio and 90% confidence interval (CI) were based on adjusted geometric mean. Natural log-transformed change from baseline in Glucose AUC(2-6) was analyzed using ANCOVA with country and treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%)</param_type>
            <param_value>86.72</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>81.13</ci_lower_limit>
            <ci_upper_limit>92.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio and 90% confidence interval (CI) were based on adjusted geometric mean. Natural log-transformed change from baseline in Glucose AUC(2-6) was analyzed using ANCOVA with country and treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%)</param_type>
            <param_value>91.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.24</ci_lower_limit>
            <ci_upper_limit>97.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio and 90% confidence interval (CI) were based on adjusted geometric mean. Natural log-transformed change from baseline in Glucose AUC(2-6) was analyzed using ANCOVA with country and treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%)</param_type>
            <param_value>87.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>81.44</ci_lower_limit>
            <ci_upper_limit>93.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio and 90% confidence interval (CI) were based on adjusted geometric mean. Natural log-transformed change from baseline in Glucose AUC(2-6) was analyzed using ANCOVA with country and treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%)</param_type>
            <param_value>77.95</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>72.91</ci_lower_limit>
            <ci_upper_limit>83.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG)</title>
        <description>The average of the Day -1 (hour -48), Day 0 (hour -24) and Day 1 pre-dose (hour 0) measurements was the baseline for fasting plasma glucose (FPG) analyses.</description>
        <time_frame>Baseline: hour -48 on Day -1, hour -24 on Day 0, and hour 0 (before morning dose) on Day 1; hour 0 (before morning dose of each day) on Days 1, 2, 3, 6, and 10; and 24 hours after Day 14 morning dose on Day 15</time_frame>
        <population>The pharmacodynamic analysis population was defined as all randomized participants who received at least 1 dose of study medication (PF-04991532 or placebo) and had at least 1 of the pharmacodynamic parameters of interest; &quot;n&quot; is the number of participants analyzed for each day.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>PF-04991532 matching placebo orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04991532 25 mg</title>
            <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04991532 75 mg</title>
            <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04991532 150 mg</title>
            <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O5">
            <title>PF-04991532 300 mg</title>
            <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG)</title>
          <description>The average of the Day -1 (hour -48), Day 0 (hour -24) and Day 1 pre-dose (hour 0) measurements was the baseline for fasting plasma glucose (FPG) analyses.</description>
          <population>The pharmacodynamic analysis population was defined as all randomized participants who received at least 1 dose of study medication (PF-04991532 or placebo) and had at least 1 of the pharmacodynamic parameters of interest; &quot;n&quot; is the number of participants analyzed for each day.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 (n=16, 17, 16, 16, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.19" spread="17.77"/>
                    <measurement group_id="O2" value="-5.04" spread="10.43"/>
                    <measurement group_id="O3" value="-4.33" spread="18.15"/>
                    <measurement group_id="O4" value="0.29" spread="14.93"/>
                    <measurement group_id="O5" value="-5.55" spread="36.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n=16, 17, 16, 16, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="15.76"/>
                    <measurement group_id="O2" value="-8.92" spread="11.86"/>
                    <measurement group_id="O3" value="-2.15" spread="15.25"/>
                    <measurement group_id="O4" value="0.23" spread="14.06"/>
                    <measurement group_id="O5" value="-7.78" spread="16.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 (n=16, 16, 16, 16, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.44" spread="26.69"/>
                    <measurement group_id="O2" value="-9.40" spread="16.68"/>
                    <measurement group_id="O3" value="-9.90" spread="18.13"/>
                    <measurement group_id="O4" value="-6.33" spread="12.24"/>
                    <measurement group_id="O5" value="-16.90" spread="23.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10 (n=16, 16, 16, 16, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.88" spread="43.97"/>
                    <measurement group_id="O2" value="-17.21" spread="24.08"/>
                    <measurement group_id="O3" value="-16.96" spread="26.78"/>
                    <measurement group_id="O4" value="-10.33" spread="15.75"/>
                    <measurement group_id="O5" value="-17.40" spread="30.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=16, 16, 16, 16, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00" spread="26.90"/>
                    <measurement group_id="O2" value="-17.83" spread="25.71"/>
                    <measurement group_id="O3" value="-14.52" spread="23.08"/>
                    <measurement group_id="O4" value="-7.27" spread="8.78"/>
                    <measurement group_id="O5" value="-11.40" spread="19.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (n=16, 16, 16, 16, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.63" spread="44.47"/>
                    <measurement group_id="O2" value="-9.71" spread="25.96"/>
                    <measurement group_id="O3" value="-8.15" spread="22.81"/>
                    <measurement group_id="O4" value="-0.58" spread="16.71"/>
                    <measurement group_id="O5" value="-4.22" spread="37.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 2 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 2</param_type>
            <param_value>100.04</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.70</ci_lower_limit>
            <ci_upper_limit>107.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 2 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 2</param_type>
            <param_value>99.44</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.04</ci_lower_limit>
            <ci_upper_limit>107.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 2 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 2</param_type>
            <param_value>101.67</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.10</ci_lower_limit>
            <ci_upper_limit>109.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 2 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 2</param_type>
            <param_value>96.82</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.69</ci_lower_limit>
            <ci_upper_limit>104.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 3 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 3</param_type>
            <param_value>95.85</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.82</ci_lower_limit>
            <ci_upper_limit>103.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 3 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 3</param_type>
            <param_value>98.71</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.37</ci_lower_limit>
            <ci_upper_limit>106.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 3 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 3</param_type>
            <param_value>99.72</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.30</ci_lower_limit>
            <ci_upper_limit>107.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 3 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 3</param_type>
            <param_value>94.49</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.53</ci_lower_limit>
            <ci_upper_limit>102.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 6 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 6</param_type>
            <param_value>93.43</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.50</ci_lower_limit>
            <ci_upper_limit>100.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 6 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 6</param_type>
            <param_value>92.71</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.81</ci_lower_limit>
            <ci_upper_limit>100.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 6 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 6</param_type>
            <param_value>94.08</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.08</ci_lower_limit>
            <ci_upper_limit>101.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 6 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 6</param_type>
            <param_value>87.74</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>81.20</ci_lower_limit>
            <ci_upper_limit>94.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 10 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 10</param_type>
            <param_value>96.91</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.72</ci_lower_limit>
            <ci_upper_limit>104.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 10 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 10</param_type>
            <param_value>96.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.90</ci_lower_limit>
            <ci_upper_limit>103.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 10 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 10</param_type>
            <param_value>99.63</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.21</ci_lower_limit>
            <ci_upper_limit>107.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 10 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 10</param_type>
            <param_value>94.50</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.46</ci_lower_limit>
            <ci_upper_limit>102.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 14 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 14</param_type>
            <param_value>86.75</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>80.32</ci_lower_limit>
            <ci_upper_limit>93.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 14 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 14</param_type>
            <param_value>87.87</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>81.34</ci_lower_limit>
            <ci_upper_limit>94.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 14 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 14</param_type>
            <param_value>91.35</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.55</ci_lower_limit>
            <ci_upper_limit>98.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 14 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 14</param_type>
            <param_value>88.60</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82.00</ci_lower_limit>
            <ci_upper_limit>95.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 15 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 15</param_type>
            <param_value>90.45</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>83.75</ci_lower_limit>
            <ci_upper_limit>97.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 15 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 15</param_type>
            <param_value>90.45</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.03</ci_lower_limit>
            <ci_upper_limit>98.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 15 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 15</param_type>
            <param_value>94.75</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.69</ci_lower_limit>
            <ci_upper_limit>102.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio of log-transformed change from baseline and 90% confidence interval (CI) of log-transformed change from baseline at Day 15 were based on adjusted geometric mean. Natural log-transformed change from baseline in FPG was analyzed using mixed effects model with country, treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%) at Day 15</param_type>
            <param_value>93.18</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.17</ci_lower_limit>
            <ci_upper_limit>100.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Area Under the Curve of Insulin From Time 2 to 6 Hours Post Morning Dose (Insulin AUC(2-6)) Following Mixed Meal Tolerance Test (MMTT) at Day 14</title>
        <description>Area Under the Curve of Insulin from Time 2 to 6 Hours Post Morning Dose (Insulin AUC(2-6)) was calculated based on 8 insulin measurements at prespecified time points using the linear trapezoidal method. Nominal times were used in the calculation. Liquid meal was administered 2 hours post morning dose of PF-04991532 for mixed meal tolerance test (MMTT).</description>
        <time_frame>Baseline: hours -46, -45.75, -45.5, -45, -44.5, -44, -43, -and -42 on Day -1 (Day 1 morning dose was hour 0); Day 14: 2, 2.25, 2.5, 3, 3.5, 4, 5, and 6 hours after Day 14 morning dose</time_frame>
        <population>The pharmacodynamic analysis population was defined as all randomized participants who received at least 1 dose of study medication (PF-04991532 or placebo) and had at least 1 of the pharmacodynamic parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>PF-04991532 matching placebo orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04991532 25 mg</title>
            <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04991532 75 mg</title>
            <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04991532 150 mg</title>
            <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O5">
            <title>PF-04991532 300 mg</title>
            <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Area Under the Curve of Insulin From Time 2 to 6 Hours Post Morning Dose (Insulin AUC(2-6)) Following Mixed Meal Tolerance Test (MMTT) at Day 14</title>
          <description>Area Under the Curve of Insulin from Time 2 to 6 Hours Post Morning Dose (Insulin AUC(2-6)) was calculated based on 8 insulin measurements at prespecified time points using the linear trapezoidal method. Nominal times were used in the calculation. Liquid meal was administered 2 hours post morning dose of PF-04991532 for mixed meal tolerance test (MMTT).</description>
          <population>The pharmacodynamic analysis population was defined as all randomized participants who received at least 1 dose of study medication (PF-04991532 or placebo) and had at least 1 of the pharmacodynamic parameters of interest.</population>
          <units>milliUnit*hour/liter (mU*hr/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.12" spread="117.08"/>
                    <measurement group_id="O2" value="139.40" spread="77.81"/>
                    <measurement group_id="O3" value="166.87" spread="132.39"/>
                    <measurement group_id="O4" value="111.13" spread="69.16"/>
                    <measurement group_id="O5" value="276.61" spread="313.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Day 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.96" spread="18.09"/>
                    <measurement group_id="O2" value="15.87" spread="27.16"/>
                    <measurement group_id="O3" value="-3.06" spread="32.79"/>
                    <measurement group_id="O4" value="11.82" spread="24.87"/>
                    <measurement group_id="O5" value="-38.06" spread="73.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio and 90% confidence interval (CI) were based on adjusted geometric mean. Natural log-transformed change from baseline in Insulin AUC(2-6) (Day 14) was analyzed using ANCOVA with country and treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%)</param_type>
            <param_value>112.83</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.84</ci_lower_limit>
            <ci_upper_limit>127.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio and 90% confidence interval (CI) were based on adjusted geometric mean. Natural log-transformed change from baseline in Insulin AUC(2-6) (Day 14) was analyzed using ANCOVA with country and treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%)</param_type>
            <param_value>102.11</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>90.78</ci_lower_limit>
            <ci_upper_limit>114.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio and 90% confidence interval (CI) were based on adjusted geometric mean. Natural log-transformed change from baseline in Insulin AUC(2-6) (Day 14) was analyzed using ANCOVA with country and treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%)</param_type>
            <param_value>111.04</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.50</ci_lower_limit>
            <ci_upper_limit>125.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio and 90% confidence interval (CI) were based on adjusted geometric mean. Natural log-transformed change from baseline in Insulin AUC(2-6) (Day 14) was analyzed using ANCOVA with country and treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%)</param_type>
            <param_value>96.73</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.46</ci_lower_limit>
            <ci_upper_limit>109.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Area Under the Curve of C-peptide From Time 2 to 6 Hours Post Morning Dose (C-peptide AUC(2-6)) Following Mixed Meal Tolerance Test (MMTT) at Day 14</title>
        <description>Area Under the Curve of C-peptide from Time 2 to 6 Hours Post Morning Dose (C-peptide AUC(2-6)) was calculated based on 8 C-peptide measurements at prespecified timepoints using the linear trapezoidal method. Nominal times were used in the calculation. Liquid meal was administered 2 hours post morning dose of PF-04991532 for mixed meal tolerance test (MMTT).</description>
        <time_frame>Baseline: hours -46, -45.75, -45.5, -45, -44.5, -44, -43, -and -42 on Day -1 (Day 1 morning dose was hour 0); Day 14: 2, 2.25, 2.5, 3, 3.5, 4, 5, and 6 hours after Day 14 morning dose</time_frame>
        <population>The pharmacodynamic analysis population was defined as all randomized participants who received at least 1 dose of study medication (PF-04991532 or placebo) and had at least 1 of the pharmacodynamic parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>PF-04991532 matching placebo orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04991532 25 mg</title>
            <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04991532 75 mg</title>
            <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04991532 150 mg</title>
            <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O5">
            <title>PF-04991532 300 mg</title>
            <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Area Under the Curve of C-peptide From Time 2 to 6 Hours Post Morning Dose (C-peptide AUC(2-6)) Following Mixed Meal Tolerance Test (MMTT) at Day 14</title>
          <description>Area Under the Curve of C-peptide from Time 2 to 6 Hours Post Morning Dose (C-peptide AUC(2-6)) was calculated based on 8 C-peptide measurements at prespecified timepoints using the linear trapezoidal method. Nominal times were used in the calculation. Liquid meal was administered 2 hours post morning dose of PF-04991532 for mixed meal tolerance test (MMTT).</description>
          <population>The pharmacodynamic analysis population was defined as all randomized participants who received at least 1 dose of study medication (PF-04991532 or placebo) and had at least 1 of the pharmacodynamic parameters of interest.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.79" spread="6.08"/>
                    <measurement group_id="O2" value="17.04" spread="6.73"/>
                    <measurement group_id="O3" value="17.20" spread="5.89"/>
                    <measurement group_id="O4" value="15.23" spread="4.51"/>
                    <measurement group_id="O5" value="19.21" spread="7.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Day 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="2.15"/>
                    <measurement group_id="O2" value="1.34" spread="2.64"/>
                    <measurement group_id="O3" value="-1.53" spread="2.88"/>
                    <measurement group_id="O4" value="-0.55" spread="1.63"/>
                    <measurement group_id="O5" value="-2.12" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio and 90% confidence interval (CI) were based on adjusted geometric mean. Natural log-transformed change from baseline in C-peptide AUC(2-6) (Day 14) was analyzed using ANCOVA with country and treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%)</param_type>
            <param_value>107.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.69</ci_lower_limit>
            <ci_upper_limit>116.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio and 90% confidence interval (CI) were based on adjusted geometric mean. Natural log-transformed change from baseline in C-peptide AUC(2-6) (Day 14) was analyzed using ANCOVA with country and treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%)</param_type>
            <param_value>92.57</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.26</ci_lower_limit>
            <ci_upper_limit>100.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio and 90% confidence interval (CI) were based on adjusted geometric mean. Natural log-transformed change from baseline in C-peptide AUC(2-6) (Day 14) was analyzed using ANCOVA with country and treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%)</param_type>
            <param_value>96.07</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.51</ci_lower_limit>
            <ci_upper_limit>104.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Test-to-Reference ratio and 90% confidence interval (CI) were based on adjusted geometric mean. Natural log-transformed change from baseline in C-peptide AUC(2-6) (Day 14) was analyzed using ANCOVA with country and treatment as fixed effect and log-transformed baseline as covariate. Placebo is the reference; the active drug group is the test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Test-to-Reference Ratio (%)</param_type>
            <param_value>91.70</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.38</ci_lower_limit>
            <ci_upper_limit>99.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Lipid Parameters at Day 14 and 16</title>
        <description>Baseline for fasting triglycerides (TG) was defined as the average of the Day -1 (hour -48), Day 0 (hour -24), and Day 1 pre-dose (hour 0) measurements. Baseline for fasting total cholesterol (TC), cholesterol (high-density lipoprotein (HDL)), and cholesterol (low-density lipoprotein (LDL)) was defined as the Day 1 pre-dose (hour 0) measurement.</description>
        <time_frame>Baseline: hour -48 on Day -1, hour -24 on Day 0, and hour 0 on Day 1 for TG and Hour 0 (before morning dose) on Day 1 for TC, HDL, and LDL; 48 hours after morning dose on Day 16 for TG and Hour 0 (before morning dose) on Day14 for TC, HDL, and LDL</time_frame>
        <population>The pharmacodynamic analysis population was defined as all randomized participants who received at least 1 dose of study medication (PF-04991532 or placebo) and had at least 1 of the pharmacodynamic parameters of interest; &quot;n&quot; is the number of participants analyzed for each day.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>PF-04991532 matching placebo orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-04991532 25 mg</title>
            <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PF-04991532 75 mg</title>
            <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PF-04991532 150 mg</title>
            <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
          </group>
          <group group_id="O5">
            <title>PF-04991532 300 mg</title>
            <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Lipid Parameters at Day 14 and 16</title>
          <description>Baseline for fasting triglycerides (TG) was defined as the average of the Day -1 (hour -48), Day 0 (hour -24), and Day 1 pre-dose (hour 0) measurements. Baseline for fasting total cholesterol (TC), cholesterol (high-density lipoprotein (HDL)), and cholesterol (low-density lipoprotein (LDL)) was defined as the Day 1 pre-dose (hour 0) measurement.</description>
          <population>The pharmacodynamic analysis population was defined as all randomized participants who received at least 1 dose of study medication (PF-04991532 or placebo) and had at least 1 of the pharmacodynamic parameters of interest; &quot;n&quot; is the number of participants analyzed for each day.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Triglycerides (Day 16) (n=16, 16, 16, 16, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.81" spread="35.87"/>
                    <measurement group_id="O2" value="12.79" spread="45.64"/>
                    <measurement group_id="O3" value="37.52" spread="98.13"/>
                    <measurement group_id="O4" value="18.24" spread="36.08"/>
                    <measurement group_id="O5" value="58.00" spread="67.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol (Day 14) (n=16, 16, 16, 15, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="16.98"/>
                    <measurement group_id="O2" value="-11.75" spread="31.62"/>
                    <measurement group_id="O3" value="4.19" spread="20.04"/>
                    <measurement group_id="O4" value="1.80" spread="19.29"/>
                    <measurement group_id="O5" value="11.38" spread="30.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol HDL (Day 14) (n=16, 16, 16, 16, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="4.48"/>
                    <measurement group_id="O2" value="-1.88" spread="7.75"/>
                    <measurement group_id="O3" value="1.88" spread="6.04"/>
                    <measurement group_id="O4" value="0.69" spread="8.44"/>
                    <measurement group_id="O5" value="3.94" spread="7.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol LDL (Day 14) (n=16, 16, 15, 14, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="17.64"/>
                    <measurement group_id="O2" value="-8.06" spread="26.98"/>
                    <measurement group_id="O3" value="4.67" spread="22.48"/>
                    <measurement group_id="O4" value="-0.79" spread="16.40"/>
                    <measurement group_id="O5" value="1.53" spread="25.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>PF-04991532 matching placebo orally twice daily for 2 weeks.</description>
        </group>
        <group group_id="E2">
          <title>PF-04991532 25 mg</title>
          <description>PF-04991532 25 milligram (mg) tablet orally twice daily for 2 weeks.</description>
        </group>
        <group group_id="E3">
          <title>PF-04991532 75 mg</title>
          <description>PF-04991532 75 mg tablet orally twice daily for 2 weeks.</description>
        </group>
        <group group_id="E4">
          <title>PF-04991532 150 mg</title>
          <description>PF-04991532 150 mg tablet orally twice daily for 2 weeks.</description>
        </group>
        <group group_id="E5">
          <title>PF-04991532 300 mg</title>
          <description>PF-04991532 300 mg tablet orally twice daily for 2 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST-T change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Parosmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

